Credit Suisse Ag Neoleukin Therapeutics, Inc. Transaction History

Credit Suisse Ag

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$0.69 - $1.33 $13 - $25	-19 Reduced 48.72%	20 $0
Q2 2022 Aug 12, 2022	BUY	$0.92 - $2.25 $35 - $87	39 New	39 $0
Q4 2021 Feb 14, 2022	SELL	$4.65 - $7.75 $82,365 - $137,275	-17,713 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$6.05 - $9.66 $387 - $618	-64 Reduced 0.36%	17,713 $128,000
Q2 2021 Aug 16, 2021	BUY	$9.23 - $13.12 $1,522 - $2,164	165 Added 0.94%	17,777 $163,000
Q1 2021 May 14, 2021	SELL	$11.26 - $15.78 $276,387 - $387,335	-24,546 Reduced 58.22%	17,612 $216,000
Q4 2020 Feb 12, 2021	BUY	$10.17 - $14.56 $280,305 - $401,302	27,562 Added 188.83%	42,158 $594,000
Q3 2020 Nov 13, 2020	BUY	$9.68 - $17.01 $141,289 - $248,277	14,596 New	14,596 $175,000

199K

Ticker NLTX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 42,579,900
Description
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of vario...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.